ASX Runners of the Week: DY6 Metals, Dateline, Andromeda & Jindalee
The company shot out of a cannon on Tuesday after it revealed that historical assays at its Tundulu REE project in Malawi features significant high-grade mineralisation of the critical mineral gallium.
A review of past drill results confirmed high-grade intercepts, including a 74-metre hit grading 93.3 grams per tonne (g/t) gallium oxide with 1.56 per cent total rare earth oxides (TREO) from 72m depth and 53m running 72.8g/t gallium with 1.02 per cent TREO.
Gallium was recently put on China's hit list for critical mineral export controls, as the metal's demand and price has steadily increased in recent years for its uses in semiconductors. China controls about 94 per cent of global gallium supply, leaving the rest of the world frantically searching for the metal, which has interestingly popped up in DY6's carbonotite hosted rare earth project.
The company noted its gallium mineralisation was open at depth, with elevated results occurring within the saprolite clays near surface and again within fresh rock at depth. It has not assayed for deeper potential.
DY6's shares promptly quadrupled on Tuesday morning peaking at 18.5 cents for a gain of 340 per cent from last week's close of 4.2c. The company was quickly placed into a speeding halt by the good boys and girls down at the ASX, who insisted the company needed to supply more evidence and documentation.
Some $1.1 million worth of stock was exchanged in its one hour of trading on Tuesday, which was the company's highest most one-day volume over the past year.
DY6 says it will now kick off critical metallurgical test work on a Tundulu bulk sample to determine if the deposit can economically produce a multiple product package.
The company says substantial potential remains for additional gallium, as only 40 per cent of the 91.5-square-kilometre project area has been drill-tested. With gallium being thrown into the mix, Tundulu's already REE-rich deposit could quickly add a valuable byproduct.
Sampling carried out by the company found mineral rich carbonatite at the previously unexplored Tundulu Hill and Makhanga Hill to the east and west of Nathace respectively.
DATELINE RESOURCES LTD (ASX: DTR)
Up 329% (0.7c – 3.0c)
Charging late this week and going down by a nose is gold and rare earths hopefully Dateline Resources. The company was touted by Donald Trump on his Truth Social platform this week, with the leader of the free world giving his seal of approval to the company's Colosseum project outside of Las Vegas.
President Trump referred to the developing gold project as 'America's second rare earths mine', noting it had been approved after years of stalled permitting. In response, Dateline's share price surged 167 per cent on Friday on $370 million worth of shares traded.
Admittedly, the project is highly prospective for rare earth elements (REE) as it sits just 10km north of the globally significant Mountain Pass REE mine. However, the company has been primarily focussed on Colosseum's 1.1-million-ounce gold endowment. Gold is the only metal that has been mined from the large open pit mine since the 1800s.
Dateline will now look to weave rare earths exploration into its ongoing development story.
The gold project is no slouch, with Dateline wrapping a robust scoping study around its deposit, outlining an 8.3-year mine life with an annual output of 75,000 ounces at an all-in sustaining cost of $2500 per ounce.
The study projects a net present value of US$235 million and a 31 per cent internal rate of return, based on a conservative gold price of US$2200 per ounce.
With gold prices now more than US$3200 per ounce, the project's economics are significantly juiced up, forecasting total sales of nearly US$1.5 billion over its lifespan.
The Trump administration appears more focused on the project's rare earth elements potential and highlighted the project as 'America's second rare earth elements mine.'
An executive order from President Donald Trump earlier this year seeking to reduce US dependence on China seems to be the driving force here, however we wonder if the gun hoe leader of the free world may have gotten his wires crossed.
ANDROMEDA METALS LTD (ASX: ADN)
up 200% (0.95c – 2.85c)
Runners' final podium finish goes to high purity alumina hopeful Andromeda Metals after the company announced it had achieved the critical four nine purity designation (4N or 99.99 per cent) for its high purity alumina (HPA) product from its Great White kaolin project in South Australia.
Kaolin is a soft white alumina clay primarily used in ceramics and paints that can also be converted to HPA for high end uses in synthetic sapphires and smart phones.
Andromeda announced that after seven years of successful metallurgical test work, the company had achieved a 99.9985 per cent purity level from its kaolin sourced at its Great White project.
The news sent its share price skyward on Thursday, hitting a top of 2.85c on $6.5M worth of paper traded, exactly 200 per cent up on its close price from last week.
Andromeda says its HPA is among the highest quality grades, which makes it ideal for applications in batteries, semiconductors, ceramics and emerging technologies.
With demand for this critical mineral projected to exceed supply by 48 per by 2028, Andromeda is looking to cash in on the growing market, using its novel process flowsheet, which was confirmed by an independent analysis to produce a premium HPA.
The company says its lab scale trials sets it apart from other HPA producers, as Andromeda's process will likely be more cost and carbon effective than other reported processes.
Following the positive results, the company will look to complete a scoping study and investigate government funding opportunities. It locked in $75M in project debt financing a little over a month ago.
JINDALEE LITHIUM LTD (ASX: JLL)
Up 158% (26c – 67c)
The final Runner and critical minerals company for the week is Jindalee Lithium. After its promising start last week, the company got a run on with our critical minerals' quartet thanks to its addition to the US's FAST-41 framework.
The framework designation signals US federal interest in projects that are of national strategic importance and promises them a fast track to eventual production.
Jindalee Lithium started the week at relatively the same levels it was last week, before the Trump administration included its flagship McDermitt Lithium project in Oregon on the incoming US FAST-41 list.
The market quickly took notice, with five solid days of volume sending its share price to a high of 67c on Thursday, up 41c to a high of 67c. This was a 158 per cent increase on last week.
The company says its significant McDermitt deposit was designated a 'transparency project' under the FAST-41 framework because it has one of the biggest contained lithium resources nationally.
It was one of only 10 resource projects nationally listed in FAST-41 in a White House announcement early last week.
Jindalee has gotten busy simultaneously applying for US Department of Defence grants to co-fund a feasibility study at McDermitt. The company expects to know the success of any awards by the middle of the year.
The growing demand for domestically sourced lithium has been highlighted as a priority for the Trump administration, as have rare earths. In a struggling lithium market, getting government recognition at a counter cyclical time could be just what McDermitt needs to push on to become a producing lithium mine.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
an hour ago
- News.com.au
Break it Down: Broken Hill Mines quick to move after ASX debut
Stockhead's Break it Down brings you today's leading market news in under 90 seconds. In this episode, host Tylah Tully looks at the latest from Broken Hill Mines (ASX:BHM), which has made its ASX debut and hit the ground running with exploration at Pinnacles West, targeting silver, lead and zinc. Watch the video to learn more. While Broken Hill Mines is a Stockhead advertiser, it did not sponsor this content. Originally published as Break it Down: Broken Hill Mines quick to move after ASX debut

News.com.au
an hour ago
- News.com.au
Health Check: On Lamington Day, biotechs serve up their chocolate-dipped quarterly morsels
Today's news is all sweet on trial progress, revenue and cash Amplia to raise capital after runaway share performance Tryptamine starts binge eating 'magic mushie' trial Today is National Lamington Day and biotechs are serving up a solid sponge-like base of news encased in chocolate and coconut – occasionally interspersed with a jam layer. Hold the cream and pink jelly though – it just doesn't work. Like so many drug discoveries, the lamington had serendipitous origins. The story goes that one of Queensland governor Lord Lamington's maids was serving up a yellow sponge, but accidentally dunked it into molten chocolate. Lord Lammo recommended the squares to be rolled into coconut shavings for ease of eating – and the rest is history. As is this non-sequitur. Now onto the biotech news. Lumos glows after last week's mega deal Point-of-care diagnostics house Lumos Diagnostics (ASX:LDX) reports revenue of $12.4 million for the year to June 30, up 12%. June quarter revenue declined 26% to $2.6 million, owing to the end of the US flu season. Lumos reported cash outflows of US$1.7 million for the quarter, taking June 30 cash to US$2 million. Investor interest has focused on last week's mega US distribution deal with Phase Scientific, which could deliver Lumos up to US$317 million ( $487 million) over six years. This pertains to the company's bacterial-versus-viral rapid lateral flow test, Febridx. Lumos has also signed a term sheet for a $5 million loan facility, proffered by shareholders Tenmile Ventures (Andrew Forrest) and Ryder Capital. At its discretion, Lumos can draw down the facility over the next 12 months. Cleo eyes FDA approval for ovarian cancer assay Still on diagnostics, Cleo Diagnostics (ASX:COV) says it aims to submit a US Food & Drug Administration (FDA) marketing approval application for its ovarian cancer assay next year. The company is on track to complete a supportive US trial in the December quarter. Thanks to government grants and tax incentives, Cleo reported cash inflows of $38,000, taking end of quarter cash to $6.46 million. Turning to drug development, genetic disease specialist PYC Therapeutics (ASX:PYC) reports cash outflows of $17.6 million. At quarter's end the company still had cash of $153 million. The company has dosed the first patient in a combined phase 1a/2b trial for polycystic kidney disease. PYC has achieved 'alignment' with the FDA on the structure of a registrational trial for its lead program, the blinding eye disease retinitis pigmentosa type 11. The company believes the regulator will require only a phase II trial. Tryptamine BEDS down eating disorder trial Psychedelic medicines house Tryptamine Therapeutics (ASX:TYP) has started recruiting patients for a world-first binge eating disorder (BED) study. In the open-label trial, 12 patients will be administered intravenously infused psilocybin, combined with psychotherapy. Melbourne's Swinburne University is undertaking the study, with first dosing this quarter and top line results due by the end of the year. BED is the most common eating disorder in the US and second most prevalent in Australia here. The condition can result in depression, anxiety, post-traumatic stress disorder and compulsive behaviour. Amplia passes the hat Meanwhile Amplia (ASX:ATX) shares this morning entered trading halt, ahead of a share placement and share purchase plan. Amplia thus continues the rich tradition of companies leveraging clinical trial results, in this case its stunning data for hard-to-treat pancreatic disease. Amplia has reported 17 'partial response' rates in it Accent trial, in 17 out of 55 advanced disease patients. A confirmed partial response is tumour shrinkage of more than 30%, sustained for two or more months with no new cancerous lesions detected. Amplia is testing AMP-945 (narmafotinib). AMP-945 appears to inhibit the protein FAK, which is overexpressed in pancreatic cancers. Amplia shares have surged 376% in the past 12 months, but investors still value the company at a modest $110 million. As of the end of March, Amplia had cash of $10.8 million. 'Perplexed' Imugene laments soft-as-a-sponge share price Imugene (ASX:IMU) chairman Paul Hopper hopes the company's lamington-soft share price will 'do an Amplia' (our words) and reflect the company's progress with its multiple cancer trials. The company last Monday announced its phase 1b study for an aggressive blood cancer had resulted in two additional 'complete responses' (that is, the tumours disappeared). Imugene is trialing Azer-cel, its allogeneic Car-T drug made from healthy donor T-cells rather than the patient's. Naturally, Imugene announced a $22.5 million and share purchase plan for up to $15 million. On reinstatement, the shares lost 4.5 cents, or 10%, taking the loss over the past year to around 80%. This allows for a one for 34 share consolidation. 'We are very disappointed with the share price performance,' Hopper says. 'We are perplexed why we had such a lukewarm reception to the earlier data at the start of year.' Cashed up for pivotal trial But with the share raising in train, Imugene investors should no longer fear that such a dilutionary event is around the corner. Post raising Imugene should have cash of $64 million, with management costing a 60-80 patient pivotal trial at $30-40 million. If approved, Azer-cel would be the first commercial allogenic Car-T treatment, enabling mass produced, off-the-shelf therapies. 'We are in active discussions with partners on the strategy for developing the drug and getting it approved,' Hopper says. Shares settle in orbit after last week's Meso-blast off Mesoblast (ASX:MSB) shares have taken a breather after Friday's 35% surge on the back of initial US sales of its first US-approved stem cell product. The company reported unaudited June quarter revenue of US$13.2 million ($20.3 million) for Ryoncil, its treatment for childhood graft-versus-host disease. The FDA approved Ryoncil in December last year. Mesoblast founder and CEO Prof Silviu Itescu points to higher sales in the current quarter, given US Centres for Medicare and Medicaid Services coverage became effective on July 1. The company has signed up more than 25 transplant centres and hopes to enlist all 45 priority centres by October. Bell Potter analyst John Hester says the sales were in line with the firm's expectations. 'The figure is inclusive of sales to the distributor, nevertheless it represents a reasonable proxy for hospital demand.' The firm values Mesoblast at $3.50 a share, implying 55% of upside.

News.com.au
an hour ago
- News.com.au
Lunch Wrap: ASX plunges but Broken Hill Mines makes stunning debut, up over 100pc
ASX cops worst hit since April as banks and CSL tumble Copper shines, Regis Resources slips Broken Hill Mines makes stunning ASX debut If you were hoping for a quiet Monday, this wasn't it. The ASX burst out and ran headfirst into a brick wall today, down 1% by lunch as it logged its worst day since April. On Friday, Wall Street ended the week a bit all over the shop. The Dow dipped 0.3%, the S&P was flat, and the Nasdaq eked out a tiny gain. Copper and aluminium rallied, with hopes of a US-China trade deal breathing a bit of life into base metals. Gold also climbed as geopolitical jitters and a soft US dollar sparked a bit of safe-haven buying. But back to the ASX where 9 out of 11 sectors were in the red this morning. And if you squinted just right, you could almost see the June quarter gains evaporating in real time. Leading the charge down were the banks and healthcare sectors. CSL (ASX:CSL), fresh off its best run since late 2021 on no real updates, dropped 1.5%. Wesfarmers (ASX:WES) wasn't feeling too flash either, falling 1.4% and dragging consumer stocks with it. But it was the big banks that really got belted. Westpac (ASX:WBC), National Australia Bank (ASX:NAB), Australia and New Zealand Banking Group (ASX:ANZ) and Commonwealth Bank (ASX:CBA) shed around 2% each. Morningstar reckons ASX shares are still trading about 4% above fair value, and judging by today's action, it looks like the market finally realised it might be time for a little trim and tuck. Amid the wreckage, AMP (ASX:AMP) shares surged nearly 9% to a five-month high after the company posted its first positive net inflows in super since 2017. South32 (ASX:S32) was another bright spot amongst the large caps this morning, jumping about 3% after nailing 102% of its full-year production guidance. Copper production was up 20%, aluminium rose 6%, and the company returned US$350 million to shareholders while pocketing another US$176 million from its Sierra Gorda copper JV. Regis Resources (ASX:RRL), meanwhile, is snapping up the Southern Star gold prospect from Great Southern Mining (ASX:GSN) for up to $9 million – $4 million now and the rest if gold prices pop or more gold turns up. The site is just a stone's throw from Regis' Ben Hur pit, and GSN boss Matt Keane says the deal juices GSN's coffers for serious exploration, while giving Regis a clear shot at near-term upside. ASX SMALL CAP WINNERS Here are the best performing ASX small cap stocks for July 21 : Security Description Last % Volume MktCap AIV Activex Limited 0.024 243% 9,463,201 $1,508,518 BHM Broken Hill Mines 0.480 129% 5,832,133 $22,594,508 IS3 I Synergy Group Ltd 0.004 100% 7,834,701 $3,412,600 RBR RBR Group Ltd 0.002 100% 500,000 $3,120,285 PGD Peregrine Gold 0.250 35% 1,164,189 $15,696,832 AUH Austchina Holdings 0.002 33% 250,000 $4,538,075 BLZ Blaze Minerals Ltd 0.004 33% 21,591,132 $5,335,392 CT1 Constellation Tech 0.002 33% 33,333 $2,212,101 EEL Enrg Elements Ltd 0.002 33% 73,603 $4,880,668 CUS Coppersearchlimited 0.022 29% 2,688,033 $2,728,358 TVN Tivan Limited 0.108 28% 4,450,847 $174,746,910 CRS Caprice Resources 0.061 27% 28,004,762 $32,016,302 ANO Advance Zinctek Ltd 1.040 25% 4,008 $51,996,269 AOK Australian Oil. 0.003 25% 21,000 $2,075,566 QXR Qx Resources Limited 0.005 25% 400,000 $5,241,315 IG6 Internationalgraphit 0.067 24% 370,270 $10,452,150 JAL Jameson Resources 0.070 23% 100,000 $40,419,003 LIN Lindian Resources 0.105 22% 5,562,640 $100,054,312 DES Desoto Resources 0.140 22% 1,716,103 $21,473,312 OEC Orbital Corp Limited 0.145 21% 710,425 $19,773,566 RTH Ras Tech 1.135 21% 41,317 $43,922,171 IRD Iron Road Ltd 0.030 20% 191,937 $20,767,319 DTI DTI Group Ltd 0.006 20% 650,000 $4,485,514 FBR FBR Ltd 0.006 20% 2,474,626 $28,447,261 ActivEX (ASX:AIV) has delivered a maiden gold resource at the historic Mt Hogan mine, confirming 310,000 ounces at 1.13g/t gold across 8.5 million tonnes. The resource sits on just a sliver of an 8km mineralised trend, with more upside likely across the broader Gilberton project, which also includes the Josephine and Comstock historic gold centres. MD Mark Derriman said the milestone caps off years of drilling, and marks a key step in the company's focus on Mt Hogan's potential. Silverâ€'leadâ€'zinc explorer Broken Hill Mines (ASX:BHM) made a cracking debut on the ASX today, with shares up more than 120% after completing its public listing under the ticker BHM. It's already stuck the drill bit in at its Pinnacles Mine, kicking off a 4000m program aimed at growing both the size and grade of its current 6Mt resource, which runs at an impressive 10.9% ZnEq. BHM's also got another 3000m of earlier drill core from Pinnacles in the queue for assays, with first results expected in the next month or so. RBR Group (ASX:RBR) said it's right where it needs to be as Mozambique's LNG megaprojects roar back to life. It's the only ASX-listed company with direct exposure to the restart of TotalEnergies and ExxonMobil's multi-billion-dollar gas plays, with construction activity expected to ramp up from mid-2025. The company said it's got boots on the ground, offering training, labour hire and camp infrastructure. Blaze Minerals (ASX:BLZ) has locked in its 80% stake in Congo Shining SARL, giving it control of the Loulombo Base Metals Project in the Republic of the Congo. The project covers 195km2 and includes the high-grade Mimpala Target, where early fieldwork has turned up strong results. Blaze is well into the prep work for its maiden drill campaign, with environmental and community engagement steps nearly wrapped up. ASX SMALL CAP LOSERS Here are the worst performing ASX small cap stocks for July 21 : Code Name Price % Change Volume Market Cap GGE Grand Gulf Energy 0.002 -33% 2,873,646 $8,461,275 VIG Victor Group Hldgs 0.040 -27% 115,254 $35,872,467 GTR Gti Energy Ltd 0.003 -25% 3,438,837 $14,835,762 SHP South Harz Potash 0.003 -25% 800,000 $5,132,248 ALM Alma Metals Ltd 0.004 -20% 11,411,588 $9,253,686 MEM Memphasys Ltd 0.004 -20% 181,616 $9,917,991 RGL Riversgold 0.004 -20% 289,833 $8,418,563 ROG Red Sky Energy. 0.004 -20% 561,454 $27,111,136 TMX Terrain Minerals 0.002 -20% 497,500 $6,329,536 VRC Volt Resources Ltd 0.004 -20% 4,597,254 $23,424,247 RDG Res Dev Group Ltd 0.009 -18% 824,238 $32,459,439 AUK Aumake Limited 0.003 -17% 2,055,000 $9,070,076 MSG Mcs Services Limited 0.005 -17% 122,300 $1,188,598 PRM Prominence Energy 0.003 -17% 208,662 $1,459,411 SLZ Sultan Resources Ltd 0.005 -17% 28,000 $1,388,819 DUN Dundasminerals 0.016 -16% 119,855 $2,037,149 KPO Kalina Power Limited 0.011 -15% 4,100,555 $38,128,944 REE Rarex Limited 0.023 -15% 6,167,708 $24,844,429 AJX Alexium Int Group 0.006 -14% 87,872 $11,105,001 EMT Emetals Limited 0.003 -14% 45,000 $2,975,000 HHR Hartshead Resources 0.006 -14% 269,666 $19,660,775 SPX Spenda Limited 0.006 -14% 1,415,869 $32,306,508 TMS Tennant Minerals Ltd 0.006 -14% 256,748 $7,461,233 WHK Whitehawk Limited 0.013 -13% 434,004 $11,120,196 IN CASE YOU MISSED IT Sipa Resources (ASX:SRI) has drilled 13 holes across the newly acquired Nuckulla Hill project in the hunt for gold near the 1.6Moz Tunkillia deposit. Norfolk Metals (ASX:NFL) has secured approval to start its maiden drilling program at the Carmen copper project in Chile. Firetail Resources (ASX:FTL) has maiden exploration underway for a high-grade gold campaign at the Excelsior project in Nevada. LAST ORDERS Omega Oil and Gas (ASX:OMA) has added $7.3m to the war chest with a research and development refund from the Australian Government, strengthening OMA's balance sheet as it works to develop the Canyon oil and gas project in the Taroom Trough. DY6 Metals (ASX:DY6) has expanded the Central rutile project in Cameroon, adding three new licences to grow the total landholding to 5901km2. All three licences demonstrate promising geology, with rock units similar to primary sources of rutile in the region – DY6 will expand its ongoing soil sampling program to cover the new ground as well. Red Metal (ASX:RDM) is preparing to put the drill bit to work in a proof-of-concept drilling program at the Pardoo gold project, within the fertile Pilbara Craton of WA. The Craton is also home to the 6Moz gold Hemi gold deposit, recently acquired for A$6 billion by Northern Star Resources (ASX:NST). RDM is targeting Hemi lookalikes in the form of discrete bullseye magnetic targets with eight drill holes over about 2000m to begin in August. At Stockhead, we tell it like it is. While Omega Oil and Gas, DY6 Metals and Red Metal are Stockhead advertisers, they did not sponsor this article.